About 119,000 results
Open links in new tab
  1. Tempus | AI-Powered Precision Medicine & Genomic Testing

    Tempus has built the world’s largest library of clinical & molecular data and an operating system to make that data accessible and useful, starting with cancer.

  2. Tempus AI - Wikipedia

    Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, [5] for oncology, cardiology, radiology, and depression. The company went public on the …

  3. Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast …

    3 days ago · Tempus AI, Inc. (NASDAQ:TEM) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. On March 3, the company announced a strategic partnership with Merck to fast-track …

  4. Tempus Hub

    Tempus Hub provides a secure platform for managing your Tempus-related activities and information.

  5. AI-Powered Tempus Inks New Multi-Year Merck Deal - Benzinga

    Mar 3, 2026 · Tempus AI expands its Merck deal as markets slide. Analysts stay bullish, but the stock trades near 52-week lows.

  6. Tempus AI outlines $1.59B 2026 revenue target with 25% growth …

    Tempus AI (TEM) Q4 2025 earnings call recap: 33%+ core growth, 69% Insights surge, $1.59B 2026 guide, $65M EBITDA, ASP upside—read now.

  7. Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast …

    4 days ago · Tempus AI, Inc. (NASDAQ:TEM) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. On March 3, the company announced a strategic partnership with Merck to fast-track …

  8. Tempus | Accounts

    Trouble logging in?

  9. Permanent Emergency (Veterinarian) Job in Lubbock, Texas - Tempus ...

    I am happy for Tempus Recruitment contact me by text/SMS. By subscribing, you consent to receive SMS messages from Tempus Recruitment. You can opt out at any time by replying to a message …

  10. Should You Buy, Hold or Sell Tempus AI Stock Heading Into 2026?

    2 days ago · TEM eyes 2026 growth by scaling diagnostics, MRD testing and AI-driven clinical apps as revenues surge 83%, though valuation concerns temper the outlook.